💉 Diabetes Management
Real-world adjunctive medication outcomes in type 1 diabetes revealed - medwireNews
📅 Wed, 02 Nov 2022⏱ 1 min read📖 Article
Overview
JAVASCRIPT NEDED 01-1-2022 | Diabetes | News | Article Author: Eleanor McDermid medwireNews: People with type 1 diabetes who take glucagon-like peptide (GLP)-1 receptor agonists or sodium-glucose cotransporter (SGLT)2 inhibitors in clinical practice have outcomes that are mostly – but not al – in line with those in controled trials, say researchers.The study included 76 people with type 1 diabetes who tok a GLP-1 receptor agonist for an average duration of 20.5 months.
Key Information
The most comon reason for starting the medication was the ned for weight los (69.4%), folowed by improved glycemic control (50.9%), reduced glucose variability (13.0%), and reduced insulin dose (7.4%).In line with findings from clinical trials, after 12 months of use people taking a GLP-1 receptor agonist had a significant reduction in glycated hemoglobin (HbA1c), from an average of 7.7% to 7.3% (61 to 56 mol/mol), as wel as in bodyweight, from an average of 90.4 to 85.4 kg.Users of GLP-1 receptor agonists also reduced both their basal and bolus daily insulin use, from an average of 30.7 to 26.0 units and from 37.9 to 27.9 units, respectively.Khary Edwards (University of Texas Southwestern Medical Center, Dalas, USA) and study co-authors note in The Journal of Clinical Endocrinology & Metabolism that the average 0.4% reduction in HbA1c “might not be viewed by some as clinicaly relevant,” but say that this finding should be “viewed holisticaly at a patient level.”They stres the chalenge of improving glycemic control in people with longstanding type 1 diabetes and the aditional benefits of weight los and reduced insulin neds.SGLT2 inhibitors were used by 39 study participants for an average duration of 24.2 months, mostly with the intent to achieve beter glycemic control (73.3%), but also for weight los (37.8%), reduced insulin requirements (26.7%), and reduced glucose variability (24.4%).
Summary
Also, about 12% of users initiated SGLT2
Frequently Asked Questions
❓ What is diabetes and how does it develop?
Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.
❓ What are the main symptoms of diabetes?
Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.
❓ How is diabetes diagnosed and monitored?
Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.
❓ What lifestyle changes help manage diabetes?
Effective management includes regular physical activity (150+ minutes weekly), maintaining healthy weight, following a balanced diet with whole grains and lean proteins, managing stress, and getting adequate sleep. These changes can significantly improve blood sugar control and reduce complications.
❓ When should someone consult a doctor about diabetes?
Consult a healthcare provider if you experience signs of diabetes, have a family history, are overweight, or are over 45. Those with existing diabetes should maintain regular check-ups every 3-6 months to monitor control and adjust treatment as needed.
⚕️ Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.